177770-52-4

Basic information

• Product Name: AcetaMide, N-[1-[(acetyloxy)phenylacetyl]-2-[(4-chlorophenyl)Methyl]-4-piperidinyl]-, [2S-[1(R*),2α,4β]]- (9CI)
• Synonyms: AcetaMide, N-[1-[(acetyloxy)phenylacetyl]-2-[(4-chlorophenyl)Methyl]-4-piperidinyl]-, [2S-[1(R*),2α,4β]]- (9CI);(S)-2-((2S,4R)-4-acetamido-2-(4-chlorobenzyl)piperidin-1-yl)-2-oxo-1-phenylethyl acetate
• CAS NO: 177770-52-4
• Molecular Formula: C24H27ClN2O4
• Molecular Weight: 442.93518
• Mol File: 177770-52-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AcetaMide, N-[1-[(acetyloxy)phenylacetyl]-2-[(4-chlorophenyl)Methyl]-4-piperidinyl]-, [2S-[1(R*),2α,4β]]- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMide, N-[1-[(acetyloxy)phenylacetyl]-2-[(4-chlorophenyl)Methyl]-4-piperidinyl]-, [2S-[1(R*),2α,4β]]- (9CI)(177770-52-4)
• EPA Substance Registry System: AcetaMide, N-[1-[(acetyloxy)phenylacetyl]-2-[(4-chlorophenyl)Methyl]-4-piperidinyl]-, [2S-[1(R*),2α,4β]]- (9CI)(177770-52-4)

Safety Data

• Hazardous Substances Data: 177770-52-4(Hazardous Substances Data)

Upstream product

• 183683-28-5 N-[2-(4-chlorobenzyl)piperidin-4-yl]acetamide hydrochloride 
• 28509-24-2 tert-butylmethyl ether 
• 144-55-8 sodium hydrogencarbonate 

Relevant articles and documents

Aroyl-piperidine derivatives

The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(azanaphthoyl-amino)-piperidines of the formula STR1 wherein X and Y are each independently of the other N and/or CH and the ring A is unsubstituted or mono- or poly-substituted

1-acyl-4-aliphatylaminopiperidine compounds

The invention relates to novel 1-acyl-4-aliphatylaminopiperidine compounds of STR1 formula (I), in which R1 is a benzoyl, naphthoyl or cycloalkanoyl radical which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen and/or trifluoromethyl; R2 is cycloalkyl or a phenyl or naphthyl radical which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, nitro, cyano and/or trifluoromethyl; R3 and R4 together are lower alkylene or aza-, oxa- or thia-lower alkylene; or R3 is lower alkyl, lower alkoxy-lower alky, di-lower alkylamino-lower alkyl or a radical of the formula --(CH2)n --C(=O)--R5 (Ia); and R4 is hydrogen, lower alkyl or a radical of the formula --(CH2)n --C(=O)--R5 (Ia); R5 is (i) hydrogen, alkyl or alkyl which is substituted by halogen, lower alkoxy amino or amino substituted by lower alkyl, amino-lower alkyl, mono- or di-lower alkylaminoalkyl, lower alkanoyl, lower alkoxycarbonyl or lower alkylene or aza-, oxa- or thia-lower alkylene, (ii) hydroxyl, cycloalkoxy, lower alkoxy or lower alkoxy which is substituted by lower alkoxy, amino or amino substituted by lower alkyl, amino-lower alkyl, mono- or di-lower alkylamino-alkyl, lower alkanoyl, lower alkoxycarbonyl or lower alkylene or aza-, oxa- or thia-lower alkylene, or (iii) amino or amino substituted by lower alkyl, cycloalkyl, amino-lower alkyl, mono- or di-lower alkylaminoalkyl, lower alkanoyl, lower alkoxycarbonyl or lower alkylene or aza-, oxa- or thia-lower alkylene; X1 is methyelene, ethylene, a direct bond; a free or ketalized carbonyl group or a free or etherified hydroxymethylene group and n is 0 or 1, and their salts, processes for the preparation of the compounds according to the invention, pharmaceutical compositions containing these and their use as pharmaceutical active ingredients.

Chromone Derivatives

Compounds of formula I STR1 wherein rings A and B are as defined in the specification, have valuable pharmacological properties and are particularly effective as NK1 antagonists and substance P antagonists. Said compounds are prepared in a manner known pe